title: Dabigatran, bleeding, and the regulators.
authors: Institute for Safe Medication Practices, 200 Lakeside Drive, Suite 200, Horsham, PA 19044, USA tmoore@ismp.org.
authors: Thomas J
authors: TJ
authors: Moore
authors: Institute for Safe Medication Practices, 200 Lakeside Drive, Suite 200, Horsham, PA 19044, USA.
authors: Michael R
authors: MR
authors: Cohen
authors: Risk Sciences International, Ottawa, ON, Canada University of Ottawa, Ottawa.
authors: Donald R
authors: DR
authors: Mattison
mesh_terms: D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D002986:Clinical Trials as Topic; D000069604:Dabigatran; D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D016903:Drug Monitoring; D005060:Europe; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran